Key result
Intracoronary rAAV1.SERCA2a improves LV contractility and reverses ventricular remodeling in preclinical heart failure.
Why the study?
The effects of long-term expression of SERCA2a in pre-clinical large animal models of heart failure are not known.
Does long-term overexpression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer improve systolic function and ventricular remodeling in a swine model of volume-overload heart failure?
Does long-term overexpression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer improve systolic function and ventricular remodeling in a swine model of volume-overload heart failure?
Long-term overexpression of SERCA2a via intracoronary rAAV1-mediated gene transfer improves systolic function and reverses left ventricular remodeling in a large-animal model of heart failure, establishing a foundation for clinical gene therapy trials.
Supports SERCA2a gene transfer in large-animal HF; hypothesis-generating and leaves open human translation.
OBJECTIVES: The aim of this study was to examine the effects of sarcoplasmic reticulum Ca(2+) ATPase (SERCA2a) gene transfer in a swine heart failure (HF) model. BACKGROUND: Reduced expression and activity of SERCA2a have been documented in HF. Prior studies have reported the beneficial effects of short-term SERCA2a overexpression in rodent models. However, the effects of long-term expression of SERCA2a in pre-clinical large animal models are not known. METHODS: Yorkshire-Landrace pigs were used (n = 16) to create volume overload by percutaneously severing chordae tendinae of the mitral apparatus with a bioptome to induce mitral regurgitation. At 2 months, pigs underwent intracoronary delivery of either recombinant adeno-associated virus type 1 (rAAV1) carrying SERCA2a under a cytomegalovirus promoter (rAAV1.SERCA2a) (n = 10; group 1) or saline (n = 6; group 2). RESULTS: At 2 months, study animals were found to be in a compensated state of volume-overload HF (increased left ventricular internal diastolic and systolic diameters [LVIDd and LVIDs]). At 4 months, gene transfer resulted in: 1) positive left ventricular (LV) inotropic effects (adjusted peak left ventricular pressure rate of rise (dP/dt)max/P, 21.2 +/- 3.2 s(-1) group 1 vs. 15.5 +/- 3.0 s(-1) group 2; p < 0.01); 2) improvement in LV remodeling (% change in LVIDs -3.0 +/- 10% vs. +15 +/- 11%, respectively; p < 0.01). At follow-up, brain natriuretic peptide levels remained stable in group 1 after gene transfer, in contrast to rising levels in group 2. Further, cardiac SERCA2a expression was significantly decreased in group 2 whereas in group 1 it was restored to normal levels. There was no histopathological evidence of acute myocardial inflammation or necrosis. CONCLUSIONS: Using a large-animal, volume-overload model of HF, we report that long-term overexpression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer preserved systolic function, potentially prevented diastolic dysfunction, and improved ventricular remodeling.
No takes yet. Share an insight, caveat, or question.
Kawase et al. (2008) studied Heart Failure (Volume-Overload Model) (n=16). rAAV1.SERCA2a vs. Saline was evaluated on Adjusted peak left ventricular pressure rate of rise (dP/dt)max/P (p=<0.01). Intracoronary delivery of rAAV1.SERCA2a significantly improved positive left ventricular inotropic effects (21.2 vs 15.5 s^-1) and reversed ventricular remodeling compared to saline in a swine model of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: